The US Food and Drug Administration (FDA) has cleared Aimago's new tablet-based diagnostic imaging tool to identify poorly perfused tissue.
The non-invasive EasyLDI perfusion assessment device uses the laser doppler imaging (LDI) technology to illuminate the skin, part of which is reflected by moving red blood cells.
The clinically relevant information provided by the tool helps surgeons to reduce the risk of skin necrosis and delayed healing and provide better and earlier decision-making for a range of surgical procedures.
Aimago co-founder and CEO Michael Friedrich said with the FDA clearance, the company's new diagnostic imaging tool will soon become the new reference for perfusion assessment.
"Our technology and design represent a new paradigm for skin perfusion assessment, with the potential to optimize surgeons' decision-making and greatly facilitate the achievement of successful outcomes, thereby reducing overall cost-of-care," Friedrich added.
